CYTOKINETICS INC (CYTK)       42.05  -1.07 (-2.48%)

Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program

Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach...

Interesting CYTK Put And Call Options For March 17th

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it...

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President...

These 3 “Strong Buy” Stocks Can Be Great Choices for 2023

One shouldn’t keep a myopic view of the market while building a strong and sustainable portfolio. Gains and losses are averaged out over a long...

Cytokinetics Jumps Despite Negative FDA Panel Vote on Heart Drug

Cytokinetics Inc.’s experimental heart failure drug got a negative vote from a panel of expert advisors to the US Food and Drug Administration. But, in a twist, shares are rising.

Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug

The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug.

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN...

Cytokinetics Stock Trading Halted Today

FDA Advisory Committee to Review the New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction...

Noteworthy Friday Option Activity: FRPT, HEES, CYTK

CYTK stock dips as FDA posts briefing documents on heart failure therapy (NASDAQ:CYTK)

Cytokinetics (CYTK) fell on Friday after the FDA briefing documents ahead of an advisory committee meeting on its heart failure therapy omecamtiv mecarbil. Read full story here.

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug...

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for...

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2022 it...

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the...

Noteworthy Tuesday Option Activity: CNSL, CYTK, XPEL

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional...